Novartis Stock Earnings Estimates Lifted by Zacks Research

Novartis AG (NYSE:NVS) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for Novartis in a research note issued on Tuesday, November 10th. Zacks Research analyst Team now expects that the company will earn $9.06 per share for the year, up from their prior estimate of $8.83. The consensus estimate for Novartis’ current full-year earnings is $9.04 per share. Zacks Research also issued estimates for Novartis’ Q4 2026 earnings at $2.20 EPS, Q1 2027 earnings at $2.29 EPS, Q2 2027 earnings at $2.53 EPS, Q3 2027 earnings at $2.57 EPS, Q4 2027 earnings at $2.53 EPS, FY2027 earnings at $9.91 EPS, Q1 2028 earnings at $2.45 EPS, Q2 2028 earnings at $2.70 EPS and Q3 2028 earnings at $2.73 EPS.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, July 23rd. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis in a research note on Sunday, August 9th. The Goldman Sachs Group reaffirmed a “sell” rating on shares of Novartis in a research report on Monday, September 21st. HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and lifted their price objective for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Finally, Berenberg Bank dropped their target price on Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, September 11th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $152.25.

Novartis Trading Down 0.2%

Shares of NYSE NVS opened at $163.28 on Wednesday. Novartis has a 1 year low of $123.24 and a 1 year high of $170.46. The stock has a market cap of $311.57 billion, a P/E ratio of 31.16, a price-to-earnings-growth ratio of 3.01 and a beta of 0.40. The firm has a 50-day moving average of $149.24 and a 200 day moving average of $152.44. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.88 and a quick ratio of 0.70.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.25 EPS.

Hedge Funds Weigh In On Novartis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVS. Private Wealth Asset Management LLC raised its position in Novartis by 22.8% in the 3rd quarter. Private Wealth Asset Management LLC now owns 4,821 shares of the company’s stock worth $687,000 after buying an additional 894 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Novartis by 64.2% in the third quarter. Private Advisor Group LLC now owns 47,481 shares of the company’s stock worth $6,769,000 after acquiring an additional 18,565 shares during the period. Ieq Capital LLC grew its stake in shares of Novartis by 2.7% in the third quarter. Ieq Capital LLC now owns 44,526 shares of the company’s stock worth $6,348,000 after acquiring an additional 1,168 shares during the period. Focus Advisor Solutions LLC raised its holdings in shares of Novartis by 51.9% during the third quarter. Focus Advisor Solutions LLC now owns 11,396 shares of the company’s stock valued at $1,625,000 after purchasing an additional 3,892 shares during the last quarter. Finally, Boston Partners raised its holdings in shares of Novartis by 36.4% during the third quarter. Boston Partners now owns 73,207 shares of the company’s stock valued at $10,424,000 after purchasing an additional 19,518 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.